Here’s an interesting story about a second scientist who has pleaded guilty to stealing trade secrets from GlaxoSmithKline. This was the second former scientist who had worked for the company to appear in court and plead guilty to stealing the company’s secrets to help benefit a pharmaceutical company based in China that they had been a part in establishing.
The U.S. Department of Justice reported that the trade secrets were going to be used to help set up the company called Renopharma in China. Both employees who had stolen information were reportedly Chinese or of Chinese descent.
The two scientists, along with a third party, allegedly decided to use the GSK secrets to help develop cancer therapies. The problem is that the Department of Justice claims that Renopharma is almost nothing but stolen information. The company was established using the Chinese government’s funds, adding a complication to the case and drawing the concern of the Department of Justice in particular.
The theft of trade secrets in this case could threaten GSK’s production of medications, which is detrimental to the company and to patients who could benefit from those drugs. While many people think that trade secret losses are only detrimental to the companies that have lost them, the reality is that patients may be the true individuals who suffer. By taking time and effort away from the development of products, it puts a roadblock in the way of patients receiving the medications they may benefit from in the future. The companies who lose trade secrets in this way have no option but to fight to regain them and prevent others from using them.